El Hospital Clínico Universitario de Valladolid es uno de los dos hospitales generales existentes en la capital vallisoletana. Está situado en la avenida Ramón y Cajal n.º 3 de Valladolid, en el barrio homónimo. Sirvió como heredero del Hospital Provincial de la Resurrección.​

During the past decade, Hospital Clinico Universitario de Valladolid conducted 137 clinical trials. In the 10-year time frame, 137 clinical trials started and 25 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 70 clinical trials started and 17 clinical trials were completed. i.e. 24.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Clinico Universitario de Valladolid" #1 sponsor was "Fundación GECP" with 11 trials, followed by "Eli Lilly and Company" with 8 trials sponsored, "PETHEMA Foundation" with 8 trials sponsored, "H. Lundbeck A/S" with 6 trials sponsored and "Hospital Clínico Universitario de Valladolid" with 6 trials sponsored. Other sponsors include 132 different institutions and companies that sponsored additional 99 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Clinico Universitario de Valladolid" #1 collaborator was "Boston Scientific Corporation" with 3 trials as a collaborator, "Instituto de Investigación Biomédica de Salamanca" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials as a collaborator and "Asociación Científica Pulmón y Ventilación Mecánica" with 2 trials as a collaborator. Other collaborators include 190 different institutions and companies that were collaborators in the rest 181 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Clinico Universitario de Valladolid" are "Migraine" (9 trials), "Heart Failure" (8 trials), "Non Small Cell Lung Cancer" (7 trials), "Coronary Artery Disease" (6 trials) and "Atrial Fibrillation" (5 trials). Many other conditions were trialed in "Hospital Clinico Universitario de Valladolid" in a lesser frequency.

Most popular intervention types in "Hospital Clinico Universitario de Valladolid" are "Drug" (89 trials), "Device" (33 trials), "Other" (22 trials), "Procedure" (9 trials) and "Diagnostic Test" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Carboplatin" (5 trials), "Dexamethasone" (5 trials), "Eptinezumab" (5 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Clinico Universitario de Valladolid" are 173 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are 81 active trials in "Hospital Clinico Universitario de Valladolid". 1 are not yet recruiting, 60 are recruiting, 19 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 71 completed trials in Hospital Clinico Universitario de Valladolid, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Clinico Universitario de Valladolid, 3 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 23 trials that are defined as “Not Applicable".